The decade's most triggering comedy
A medical watchdog organization has called on the Endocrine Society to perform a “systematic review” of its support for medical interventions that seek to change the sex of minors, a letter obtained exclusively by The Daily Wire reveals.
Do No Harm, an organization that seeks to “Protect healthcare from a radical, divisive, and discriminatory ideology,” highlighted growing skepticism of transgender medical interventions across Europe in a letter to the Endocrine Society. The organization has maintained its support for what it refers to as “gender-affirming care,” which includes the use of puberty blockers, cross-sex hormone therapy, and surgical interventions like double mastectomies.
“We are confounded by the Society’s avowed certainty of a favorable benefit-to-risk ratio when it comes to the medical gender transition of children,” the July 24th letter from Do No Harm reads.
The letter, signed by Do No Harm’s Chairman Stanley Goldfarb and Senior Fellow Roy Eappen, went on to state: “There is a steadily growing international consensus that the approach endorsed by the Endocrine Society is misguided and potentially dangerous to children and adolescents.”
It called for the Endocrine Society to update its guidelines on transgender medical interventions in light of changing policies in the wider Western world.
“To date and to our knowledge, the Endocrine Society has not publicly acknowledged the changes happening in Europe,” the letter adds. “If some of the most socially liberal countries in the world are wrong about the shaky empirical foundations of pediatric gender medicine, the Endocrine Society should say why.”
The letter comes after Eappen and Do No Harm Research Director Ian Kingsbury attended the Endocrine Society’s annual meeting and co-authored an article in the Wall Street Journal which said many of the society’s members were displeased with the organization’s stance on transgender medical interventions.
“We found that endocrinologists are aware of the society’s failings and rue its elevation of transgender activism over medical expertise and patient needs,” the article reads. “Without exception, they acknowledged that the society’s evidence base for pediatric gender transition is weak, at best.”
It went on to claim that “Medical professionals are being cowed into silence and coerced into providing treatments they know are dangerous to children.”
Endocrine Society President Stephen R. Hammes shot back in a letter also published in the Wall Street Journal. The brief piece claims that the initial article “ignores scientific evidence and the conclusions reached by the American Medical Association, the American Academy of Pediatrics and other reputable medical organizations.”
While the Endocrine Society responded to the op-ed in the Wall Street Journal, it has not responded to the letter from Do No Harm.
The Endocrine Society has received funding from at least one business that profits from medical transitions. The organization received nearly $100,000 from pharmaceutical company Abbvie from 2019 to 2021. Abbvie creates Lupron Depot, a drug that has been used to chemically castrate sex offenders and is commonly used off-label to block puberty in adolescents who identify as transgender.
Although the Endocrine Society did not respond to the letter from Do No Harm and has made no indication that it would reconsider its stance on transgender medical interventions, the American Academy of Pediatrics recently announced that it would be conducting a review of the evidence surrounding “gender-affirming care.”
The Endocrine Society did not respond to a request for comment.